PharmGKB summary: gemcitabine pathway

Pharmacogenet Genomics. 2014 Nov;24(11):564-74. doi: 10.1097/FPC.0000000000000086.

Authors

Maria L Alvarellos¹, Jatinder Lamba, Katrin Sangkuhl, Caroline F Thorn, Liewei Wang, Daniel J Klein, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California, USA cDepartment of Pharmacotherapy and Translational Research dCenter for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida eDepartment of Molecular Pharmacology & Experimental Therapeutics, Division of Clinical Pharmacology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / pharmacokinetics
Antimetabolites, Antineoplastic / pharmacology*
Deoxycytidine / analogs & derivatives*
Deoxycytidine / pharmacokinetics
Deoxycytidine / pharmacology
Gemcitabine
Humans
Pharmacogenetics*

Substances

Antimetabolites, Antineoplastic
Deoxycytidine
Gemcitabine

Grants and funding